CHSY1 Antibody

What is CHSY1 and why is it significant in biological research?

CHSY1 (chondroitin sulfate synthase 1) is a critical enzyme involved in the biosynthesis of chondroitin sulfate chains, playing essential roles in developmental processes and disease pathogenesis. This protein possesses both beta-1,3-glucuronic acid and beta-1,4-N-acetylgalactosamine transferase activities, which are essential for the polymerization of chondroitin sulfate, a major component of the extracellular matrix . The human version of CHSY1 has a canonical amino acid length of 802 residues and a protein mass of approximately 91.8 kilodaltons . CHSY1 is primarily localized in the Golgi apparatus and is secreted from cells . Research interest in CHSY1 has intensified due to its upregulation in various cancers, particularly gastric cancer, and its potential as both a prognostic marker and therapeutic target . Additionally, CHSY1 plays significant roles in nerve regeneration processes, making it relevant for neurological research .

What sample types can be effectively detected using CHSY1 antibodies?

CHSY1 antibodies have demonstrated effectiveness in detecting the target protein across multiple sample types. In research applications, these antibodies have been successfully used to detect CHSY1 in:

• Cell lysates from various human and mouse cell lines, particularly in gastric cancer cell models

• Tissue sections from both normal and pathological samples, including gastric cancer tissues

• Nerve tissue samples, where CHSY1 expression has been observed in axons and Schwann cells

• Regenerating nerve tissue, where differential expression patterns can be observed compared to normal tissue

The detection method depends on the specific experimental requirements, with CHSY1 antibodies being suitable for applications including Western blot, immunohistochemistry, flow cytometry, and ELISA . When working with nerve tissue samples, CHSY1 antibodies have shown particular utility in confocal microscopy studies when paired with neural markers such as β3-tubulin .

How should CHSY1 antibodies be stored and handled to maintain optimal activity?

For optimal preservation of CHSY1 antibody activity, follow these evidence-based handling protocols:

• Long-term storage: Store antibodies at -20°C for up to one year. Commercial CHSY1 antibodies are typically supplied in a stabilized solution containing PBS with 50% glycerol, 0.5% BSA, and 0.02% sodium azide .

• Short-term storage: For frequent use within a one-month period, storage at 4°C is acceptable and prevents repeated freeze-thaw cycles .

• Freeze-thaw considerations: Minimize freeze-thaw cycles as they can significantly degrade antibody quality. If multiple uses are anticipated, consider aliquoting the antibody into smaller volumes before freezing.

• Working dilutions: Prepare working dilutions on the day of use. For Western blot applications, dilution ratios typically range from 1:500 to 1:2000, though optimal conditions should be determined empirically for each specific application.

• Contaminant prevention: Use sterile techniques when handling antibodies to prevent microbial contamination, despite the presence of sodium azide as a preservative in most commercial preparations.

What are the optimal protocols for using CHSY1 antibodies in immunohistochemistry of nerve tissue?

When conducting immunohistochemistry of nerve tissue using CHSY1 antibodies, researchers should follow these optimized protocols based on successful published research:

• Tissue preparation:

  • Fix tissue samples in 4% paraformaldehyde for 24 hours

  • Process for paraffin embedding or prepare frozen sections (10-15 μm thickness)

  • For paraffin sections, perform antigen retrieval using citrate buffer (pH 6.0) at 95°C for 20 minutes

• Immunostaining procedure:

  • Block non-specific binding with 5% normal serum (matched to secondary antibody host) in PBS containing 0.1% Triton X-100 for 1 hour at room temperature

  • Incubate with primary anti-CHSY1 antibody (1:100 to 1:200 dilution) overnight at 4°C

  • For dual labeling, co-incubate with neural markers such as anti-β3-tubulin or anti-S100 (for Schwann cells)

  • Wash thoroughly with PBS (3-5 times, 5 minutes each)

  • Incubate with appropriate fluorescently-labeled secondary antibodies for 2 hours at room temperature

  • Counterstain nuclei with DAPI if desired

  • Mount using anti-fade mounting medium

• Visualization and analysis:

  • Use confocal microscopy for optimal visualization of co-localization patterns

  • When examining nerve tissue, note that CHSY1 expression patterns differ between normal conditions (primarily axonal) and post-injury states (strong expression in Schwann cells)

  • Compare images across different time points to track changes in CHSY1 expression during nerve regeneration

This protocol has been successfully used to demonstrate that CHSY1 is mainly present in axons under normal conditions but shows increased expression in proliferative Schwann cells one month after end-to-side neurorrhaphy, with expression patterns shifting back to axons after three months .

How can Western blot protocols be optimized for CHSY1 detection in cancer tissue samples?

For optimal detection of CHSY1 in cancer tissue samples using Western blot, implement the following research-validated protocol:

• Sample preparation:

  • Extract total protein from fresh or frozen cancer tissue samples using RIPA buffer supplemented with protease inhibitors

  • Determine protein concentration using BCA or Bradford assay

  • Prepare samples containing 20-40 μg of total protein per lane

• SDS-PAGE separation:

  • Use 8-10% polyacrylamide gels (CHSY1 has a molecular weight of ~91.8 kDa)

  • Include positive controls (cell lines known to express CHSY1) and negative controls

  • Run gel at 80-120V until adequate separation is achieved

• Transfer and immunoblotting:

  • Transfer proteins to PVDF membrane (recommended over nitrocellulose for higher sensitivity)

  • Block membrane with 5% non-fat milk or 3-5% BSA in TBST for 1 hour at room temperature

  • Incubate with primary anti-CHSY1 antibody at 1:500 to 1:1000 dilution overnight at 4°C

  • Wash thoroughly with TBST (3-5 times, 5-10 minutes each)

  • Incubate with HRP-conjugated secondary antibody at 1:5000 dilution for 1 hour at room temperature

  • Wash thoroughly with TBST

• Detection and analysis:

  • Develop using enhanced chemiluminescence (ECL) substrate

  • Expected band size for CHSY1 is approximately 91.8 kDa

  • For quantitative analysis, normalize CHSY1 signal to housekeeping proteins like GAPDH or β-actin

• Validation and troubleshooting:

  • Confirm specificity using CHSY1 knockdown samples as negative controls

  • If background is high, increase washing time and decrease antibody concentration

  • For weak signals, consider using more sensitive detection systems or increasing antibody incubation time

This optimized protocol has been successfully applied in gastric cancer research, where Western blot analysis confirmed the knockdown efficiency of CHSY1-targeted siRNA treatments .

What controls should be included when validating CHSY1 antibody specificity?

Rigorous validation of CHSY1 antibody specificity requires the inclusion of these essential controls:

• Positive tissue/cell controls:

  • Gastric cancer tissue/cell lines (strongly express CHSY1)

  • Nerve tissue samples (express CHSY1 in both axons and Schwann cells)

  • Cell lines with confirmed CHSY1 expression via RT-PCR or RNA-seq data

• Negative controls:

  • Tissue/cells treated with CHSY1-specific siRNA (knockdown samples) - these show reduced CHSY1 protein levels when analyzed by Western blot

  • Primary antibody omission controls to assess non-specific binding of secondary antibodies

  • Isotype controls using non-specific IgG from the same host species as the CHSY1 antibody

• Molecular validation:

  • Verification that the detected band appears at the expected molecular weight (~91.8 kDa)

  • Peptide competition assays where pre-incubation of the antibody with the immunizing peptide should abolish specific staining

  • If possible, validation using multiple antibodies targeting different epitopes of CHSY1

• Application-specific controls:

  • For immunohistochemistry: Comparison of staining patterns with published literature, showing CHSY1 localization in Golgi apparatus and secretory pathway

  • For in vivo studies: Include appropriate vehicle controls alongside experimental treatments

In a study examining Chsy1's role in nerve regeneration, researchers effectively validated antibody specificity by correlating protein detection with mRNA levels quantified by qPCR, showing 95% knockdown efficiency at the mRNA level that corresponded with decreased protein detection by Western blot .

How can CHSY1 antibodies be used to investigate the role of CHSY1 in cancer progression?

CHSY1 antibodies can be strategically deployed to elucidate CHSY1's role in cancer progression through these advanced research approaches:

• Diagnostic and prognostic value assessment:

  • Use immunohistochemistry with CHSY1 antibodies to analyze tissue microarrays containing samples from different cancer stages

  • Correlate CHSY1 expression levels with clinical parameters, tumor stage, and patient survival

  • Research has shown that CHSY1 upregulation is associated with more advanced tumor stages and poorer prognosis in gastric cancer

• Mechanisms of cancer promotion:

  • Combine CHSY1 immunostaining with markers of proliferation (Ki-67), apoptosis (cleaved caspase-3), and migration to establish correlations

  • Use CHSY1 antibodies in chromatin immunoprecipitation (ChIP) assays to identify potential transcriptional regulators of CHSY1 in cancer cells

  • Employ co-immunoprecipitation with CHSY1 antibodies to identify protein interaction partners that may contribute to its tumor-promoting effects

• Therapeutic targeting evaluation:

  • Monitor CHSY1 protein levels via Western blot in response to potential therapeutic agents

  • Develop quantitative ELISA using CHSY1 antibodies to measure circulating CHSY1 levels as a potential biomarker

  • Use CHSY1 antibodies to validate knockdown efficiency in siRNA or CRISPR/Cas9-mediated targeting experiments

• Functional studies:

  • Compare the effects of CHSY1 knockdown and overexpression on cancer cell behavior using CHSY1 antibodies to confirm modification of protein expression

  • Investigate CHSY1's impact on the tumor microenvironment by examining chondroitin sulfate deposition in relation to CHSY1 expression levels

Research utilizing CHSY1 antibodies has demonstrated that CHSY1 knockdown inhibits gastric cancer cell proliferation, colony formation, and migration while promoting apoptosis, effects that were reversed when CHSY1 expression was restored . These findings establish CHSY1 as a potential therapeutic target in gastric cancer treatment.

What are the methodological considerations when using CHSY1 antibodies to study nerve regeneration?

When investigating nerve regeneration using CHSY1 antibodies, researchers should consider these methodological approaches based on published research:

• Temporal expression analysis:

  • Design time-course experiments to track CHSY1 expression during different phases of nerve regeneration

  • Evidence shows that CHSY1 expression shifts from axons to Schwann cells one month after injury, then returns predominantly to axons after three months

• Co-localization studies:

  • Pair CHSY1 antibodies with markers for:

    • Schwann cells (S100)

    • Regenerating axons (PGP9.5, β3-tubulin)

    • Extracellular matrix components (versican)

  • Use confocal microscopy for precise spatial resolution of expression patterns

• Functional intervention approaches:

  • Combine CHSY1 antibody staining with in vivo siRNA knockdown experiments

  • Validate knockdown efficiency at both mRNA level (qPCR) and protein level (Western blot with CHSY1 antibodies)

  • Assess functional outcomes using electrophysiological recordings (compound muscle action potential)

• Quantitative analysis methods:

  • Implement stereological counting methods to quantify CHSY1-positive cells in tissue sections

  • Use digital image analysis to measure co-localization coefficients between CHSY1 and neural markers

  • Employ Western blot densitometry to quantify changes in CHSY1 protein levels during regeneration

Research has demonstrated that silencing CHSY1 with siRNA in an end-to-side neurorrhaphy model decreased versican accumulation and promoted axonal regeneration, resulting in improved functional recovery as measured by compound muscle action potential analysis . This suggests that CHSY1 inhibition may be a promising strategy to enhance peripheral nerve regeneration.

How can researchers troubleshoot non-specific binding or weak signals when using CHSY1 antibodies?

When encountering challenges with CHSY1 antibody performance, implement these evidence-based troubleshooting strategies:

• For non-specific binding issues:

  Problem	Potential Cause	Solution
  Multiple bands in Western blot	Cross-reactivity with related proteins	Use more stringent washing conditions; increase dilution of primary antibody; try antibodies targeting different epitopes
  High background in immunohistochemistry	Insufficient blocking or antibody concentration too high	Extend blocking time to 2 hours; optimize antibody dilution (try series: 1:100, 1:200, 1:500); add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions
  Non-specific nuclear staining	Antibody accessing denatured nuclear proteins	Ensure proper fixation; use freshly prepared fixatives; try alternative fixation methods

• For weak signal issues:

  Problem	Potential Cause	Solution
  Weak bands in Western blot	Insufficient protein loading or transfer issues	Increase protein loading to 40-60 μg; optimize transfer conditions for high molecular weight proteins; use PVDF membranes instead of nitrocellulose
  Weak immunohistochemistry signal	Inadequate antigen retrieval or excessive fixation	Optimize antigen retrieval (try citrate buffer pH 6.0 vs. EDTA buffer pH 9.0); reduce fixation time; use signal amplification systems (e.g., tyramide signal amplification)
  Inconsistent results between experiments	Antibody degradation or sample variability	Aliquot antibodies to avoid freeze-thaw cycles; standardize tissue processing protocols; include positive controls in each experiment

• Advanced optimization strategies:

  • Perform epitope mapping to identify optimal antibody binding conditions

  • Consider using alternative detection systems (e.g., fluorescent vs. chromogenic)

  • For tissue work, optimize section thickness (10-15 μm for nerve tissue has shown good results)

  • Test multiple antibody incubation temperatures (4°C overnight vs. room temperature for 2 hours)

When working with nerve tissue samples, researchers have successfully detected CHSY1 using confocal microscopy with careful optimization of immunostaining protocols, resulting in clear visualization of CHSY1 expression in both axons and Schwann cells during different phases of nerve regeneration .

How does CHSY1 expression correlate with clinical outcomes in cancer research?

Research utilizing CHSY1 antibodies has revealed significant correlations between CHSY1 expression and clinical outcomes in cancer patients:

• Prognostic significance:

  • Immunohistochemical analysis of gastric cancer tissue samples has demonstrated that CHSY1 upregulation is significantly associated with more advanced tumor stages

  • Higher CHSY1 expression levels correlate with poorer prognosis in gastric cancer patients, suggesting its potential as a prognostic biomarker

  • Data mining of public databases has confirmed these clinical correlations, providing additional validation of these findings

• Correlation with clinicopathological features:

  • CHSY1 expression levels show associations with key pathological parameters including:

    • Tumor invasion depth

    • Lymph node metastasis status

    • TNM staging

  • These correlations suggest CHSY1's involvement in cancer progression mechanisms beyond primary tumor growth

• Therapeutic implications:

  • In experimental models, gastric cancer cells with CHSY1 knockdown showed:

    • Reduced tumorigenicity

    • Slower tumor growth rates in vivo

    • Increased sensitivity to certain chemotherapeutic agents

  • These findings position CHSY1 as a potential therapeutic target for developing more effective treatments for gastric cancer

Future research directions should include expanding these investigations to other cancer types, evaluating CHSY1 as a circulating biomarker, and developing therapeutic strategies targeting CHSY1 or its downstream effectors.

What experimental approaches can determine if CHSY1 could be a therapeutic target in nerve regeneration?

To evaluate CHSY1 as a potential therapeutic target for enhancing nerve regeneration, researchers should consider these experimental approaches:

• Target validation studies:

  • Genetic manipulation approaches:

    • Use siRNA-mediated knockdown of CHSY1 in nerve injury models

    • Develop conditional knockout models to assess tissue-specific effects

    • Compare outcomes with chondroitinase ABC treatment, which degrades the CS chains produced by CHSY1

  • Functional outcome assessment:

    • Electrophysiological measurements (compound muscle action potential)

    • Behavioral testing for sensory and motor recovery

    • Histological evaluation of axon regeneration and remyelination

• Mechanistic investigations:

  • Molecular pathway analysis:

    • Examine downstream effects of CHSY1 inhibition on:

      • Versican accumulation (shown to decrease with CHSY1 silencing)

      • Expression of axonal markers (PGP9.5, β3-tubulin)

      • Schwann cell activation and migration

    • Determine if effects are mediated through CS-dependent or independent mechanisms

  • Temporal considerations:

    • Establish optimal timing for intervention based on CHSY1 expression patterns

    • Research indicates CHSY1 is upregulated in Schwann cells one month after injury, suggesting this may be a critical intervention window

• Therapeutic development approaches:

  • Delivery methods optimization:

    • Test local vs. systemic administration of CHSY1 inhibitors

    • Evaluate nanoparticle-based delivery of siRNA

    • Develop hydrogel-based delivery systems for sustained release

  • Combination therapies:

    • Assess synergistic effects with growth factors

    • Combine with other ECM-modifying approaches

    • Integrate with bioengineered nerve guidance conduits

Research has demonstrated that in vivo knockdown of CHSY1 using locally injected siRNA successfully promotes axonal regeneration after end-to-side neurorrhaphy, with knockdown efficiency reaching 95% at the mRNA level . This approach showed advantages over other methods like chondroitinase ABC treatment, which completely degrades CS chains and may cause excessive sprouting .

How can multiplexed antibody techniques advance our understanding of CHSY1's interactions with other proteins?

Advanced multiplexed antibody techniques offer powerful approaches to unravel CHSY1's complex interactions with other proteins in both normal physiology and disease states:

• Multiplex immunofluorescence strategies:

  • Sequential immunostaining protocols:

    • Use tyramide signal amplification (TSA) to allow multiple antibodies from the same host species

    • Stain for CHSY1 alongside interaction partners like versican, other ECM components, and cell-specific markers

  • Spectral imaging approaches:

    • Employ multispectral imaging systems to distinguish multiple fluorophores

    • Analyze co-localization patterns at subcellular resolution

    • Quantify spatial relationships between CHSY1 and potential interacting proteins

• Protein-protein interaction analysis:

  • Proximity ligation assays (PLA):

    • Detect CHSY1 interactions with chondroitin sulfate modification enzymes

    • Investigate associations with Golgi transport proteins

    • Quantify changes in interaction patterns during disease progression

  • Co-immunoprecipitation coupled with mass spectrometry:

    • Use CHSY1 antibodies to pull down protein complexes

    • Identify novel binding partners through proteomic analysis

    • Confirm interactions using reverse co-immunoprecipitation

• Tissue and cellular context analysis:

  • Single-cell analysis techniques:

    • Combine single-cell RNA sequencing with protein detection

    • Map CHSY1 expression patterns across diverse cell populations

    • Correlate with expression of potential interaction partners

  • Tissue microenvironment examination:

    • Use multiplexed immunohistochemistry to analyze CHSY1 in relation to ECM components

    • Investigate CHSY1's role in modifying the tumor microenvironment

    • Examine interactions with cell surface receptors that bind chondroitin sulfate

Research has shown that CHSY1 expression impacts versican distribution in nerve tissue, with CHSY1 knockdown leading to decreased versican accumulation and improved axonal regeneration . These findings suggest important functional interactions between CHSY1 and versican that could be further characterized using multiplexed antibody techniques.

What are the most promising future research directions for CHSY1 antibody applications?

Based on current research findings and technological advancements, several promising directions for CHSY1 antibody applications merit further investigation:

• Biomarker development:

  • Evaluate CHSY1 as a prognostic biomarker across different cancer types, expanding beyond gastric cancer where its correlation with poor prognosis has been established

  • Develop standardized immunohistochemical scoring systems for CHSY1 expression to facilitate clinical implementation

  • Investigate circulating CHSY1 levels in patient serum as a potential non-invasive biomarker

• Therapeutic targeting approaches:

  • Design antibody-drug conjugates targeting CHSY1 in cancer cells with high expression

  • Develop siRNA delivery systems specifically targeting CHSY1 in nerve injury sites to promote regeneration

  • Create small molecule inhibitors of CHSY1 enzymatic activity for potential therapeutic applications

• Advanced imaging applications:

  • Implement multiplexed imaging approaches to study CHSY1's interactions with other proteins in tissue context

  • Develop live cell imaging techniques using fluorescently-tagged antibody fragments to track CHSY1 dynamics

  • Apply super-resolution microscopy to examine CHSY1's subcellular localization at nanoscale resolution

• Mechanistic investigations:

  • Unravel the precise molecular mechanisms by which CHSY1 influences cancer cell behavior and nerve regeneration

  • Investigate CHSY1's role in modifying the extracellular matrix and how these modifications affect cellular responses

  • Explore potential non-enzymatic functions of CHSY1 beyond its role in chondroitin sulfate synthesis

Recent research demonstrating CHSY1's role in nerve regeneration and cancer progression provides strong rationale for these future directions, with particular promise in developing targeted therapeutic approaches for both cancer treatment and enhancing nerve repair .

How can researchers integrate CHSY1 antibody data with other -omics approaches for comprehensive research insights?

Integrating CHSY1 antibody data with other -omics approaches enables comprehensive research insights through these methodological strategies:

• Multi-omics data integration frameworks:

  • Correlative analyses:

    • Combine CHSY1 protein expression data from antibody-based techniques with transcriptomic data to identify regulatory mechanisms

    • Correlate CHSY1 expression with glycomic profiles to understand functional impacts on glycosaminoglycan composition

    • Integrate with epigenomic data to identify potential regulatory elements controlling CHSY1 expression

  • Network biology approaches:

    • Construct protein-protein interaction networks centered on CHSY1

    • Develop pathway enrichment analyses incorporating CHSY1 antibody data

    • Apply machine learning algorithms to predict functional relationships from integrated datasets

• Technological integration strategies:

  • Spatial multi-omics:

    • Combine spatial transcriptomics with CHSY1 immunohistochemistry on serial sections

    • Apply digital spatial profiling to correlate CHSY1 protein levels with multiple analytes in the same tissue section

    • Develop multiplexed in situ approaches combining RNA and protein detection

  • Single-cell multi-omics:

    • Implement CITE-seq or similar approaches to simultaneously measure CHSY1 protein and transcriptome in single cells

    • Correlate with metabolomic profiles at the single-cell level

    • Develop computational methods to integrate these multi-modal data types

• Clinical and translational applications:

  • Patient stratification models:

    • Develop integrated biomarker panels combining CHSY1 protein levels with other molecular signatures

    • Create predictive models for treatment response incorporating CHSY1 expression data

    • Design precision medicine approaches based on comprehensive molecular profiling including CHSY1

  • Therapeutic development pipelines:

    • Screen for compounds affecting both CHSY1 expression and related pathways

    • Validate drug effects across multiple molecular levels

    • Monitor treatment efficacy using integrated biomarker panels

These integrative approaches can provide deeper insights into CHSY1's roles in cancer progression and nerve regeneration, potentially revealing novel therapeutic targets and biomarkers that would not be apparent from any single data type alone .